Overview

Humanized Transgenic (HuTg) Mice

With proprietary mouse platforms comes a licensing process filled with legal fees, MTAs, royalty
agreements, and restrictions. These hurdles can drain time and resources before R&D teams can begin
 in vivo discovery campaigns. Our humanized transgenic (HuTg) mouse platform is license-free,
removing burdensome administrative barriers and supporting your path to discovery.

 

 

HuTg and DiversimAb – Better Together

Wild type, knockout and humanized in vivo platforms typically yield limited epitopic diversity, meaning
fewer chances to uncover promising hits. To circumvent this, we offer to pair our HuTg mice with
 DiversimAb mice  – a platform that generates a more diverse antibody repertoire – boosting epitope
coverage, functional candidates and your chances of success.

 

Liquid Biopsy vs Traditional Methods

 
HUTG MICE OFFERED BY TWIST
DIVERSIMAB HYPERIMMUNE MICE
OTHER HUTG MICE
Licensing Required? No No Yes
Epitope Coverage and Diversity Med High Low
Affinity Range sub nM+ sub nM+ sub nM+
Binders to high homology targets or epitopes? No Yes No
Rapid (3 week) immunization available? Yes Yes No
Performance with Beacon Single B Cell Screening Good Excellent Poor
Humanization Required? No Yes No
Risk of Developability Liabilities Low Low Low
Cost Med Low High
 
Benefits

Humanized Mice: A Pathway to Preclinical Success

HuTg mice have been the origin for several commercially successful therapeutic antibodies. As in vivo 
antibody discovery evolves, humanized mouse platforms that generate robust immune responses and
human antibody repertoires are key to reducing immunogenicity, accelerating lead optimization, and
streamlining translation to the clinic.

 

 

Easing the Burden of Human Antibody Discovery

Our HuTg mice empowers your in-house antibody discovery efforts with faster timelines and at lower
upfront costs, without the administrative red tape.

 

 

Want to learn more about Twist's antibody discovery services?

Connect with one of our experts to develop a tailored project proposal to support your specific research needs.

Applications

Find Fully Human Hits in Weeks with Single B-Cell Screening

HuTg mice, like our DiversimAb platform, generate potent, highly-specific therapeutic and reagent antibody candidates. Both platforms are fully compatible with our Beacon-based single B-cell screening, enabling high-resolution, high-throughput hit identification and sequencing in a few weeks. Twist’s HuTg mouse workflow is particularly well suited for single B-cell screening, as they generate highly productive and active B cell populations, which is not typically seen with other humanized mouse platforms.

 

Hybridoma-Compatible Workflow

Twist also provides an end-to-end, adaptable hybridoma workflow for HuTg and DiversimAb mice that includes hybridoma generation, high-throughput screening, and sequencing to uncover promising hits.

Get in Touch With Us

Antibody enthusiasts are standing by and would love to hear more about your discovery needs. Challenging targets welcome!